arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked

The Future of CAR-T Cell Therapy Berlin

Berlin |
Speakers include:
Tino Sorge, MP

Tino Sorge, MP

German Bundestag

Thomas Müller

Thomas Müller

Federal Ministry of Health, Germany

Martin Bornhäuser

Martin Bornhäuser

University Hospital Carl Gustav Carus TU Dresden

Overview

Hosted by the Financial Times, in partnership with Gilead Sciences, this event will explore CAR-T cell therapy’s potential as an innovative and alternative therapeutic option.

fallback
fallback Add to my Calendar 11/08/2018 15:30:0011/08/2018 19:00:00falseThe Future of CAR-T Cell Therapy BerlinHosted by the Financial Times, in partnership with Gilead Sciences, this event will explore CAR-T cell therapy’s potential as an innovative and alternative therapeutic option.The-Future-of-CAR-T-Cell-Therapy-Berline037a85ed223006a4c0c78afb1728576MM/DD/YYYY

Full Overview

CAR-T cell therapy is an innovative approach that has the potential to change the treatment of people with certain types of cancer. With therapies already approved and being used in the United States, interest and expectations are high for the introduction of CAR-T cell therapies in Europe, after their approval for Europe and Germany in August.

Hosted by the Financial Times, in partnership with Gilead Sciences, this event will explore CAR-T cell therapy’s potential as an innovative and alternative therapeutic option.

The event will be conducted in German.

fallback

Agenda - 8th Nov

  • 3:30pm
    Arrivals
  • 4:00pm
    Welcoming Remarks

    Frederick Studemann, Literary Editor, Financial Times
    Dennis Frerichs, General Manager, Gilead Sciences 

  • 4:10pm
    The potential of CAR-T for patients with cancer

    Martin Bornhäuser, Director, Department of Internal Medicine I and National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus TU Dresden

  • 4:35pm
    A patient group perspective on the impact of living with advanced blood cancer, including diagnosis and patient experience

    Rainer Göbel, Associate, Deutsche Leukamie & Lymphom-Hilfe (DLH)

  • 4:45pm
    The opportunities and challenges for healthcare systems: how to balance access and affordability while supporting continued innovation

    Thomas Müller, Head of Directorate General , Drugs, Medical Devices, Biotechnology, Federal Ministry of Health, Germany

  • 5:00pm
    A policymaker’s view: How can politics improve the framework for the introduction of cell therapies and personaliSed medicine?

    Tino Sorge, MP Member of the Committee on Health of the German Bundestag.

  • 5:15pm
    Panel: Building a global future for CAR-T

    Martin Bornhäuser, Director, Department of Internal Medicine I and National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus TU Dresden

    Dennis Frerichs, General Manager, Gilead Sciences 

    Rainer Göbel, Associate, Deutsche Leukamie & Lymphom-Hilfe (DLH)

    Thomas Müller, Head of Directorate General , Drugs, Medical Devices, Biotechnology, Federal Ministry of Health, Germany

    Tino Sorge, MP Member of the Committee on Health of the German Bundestag

    Moderator: Sebastian Krolop, Partner and Industry Lead, Life Sciences and Health Care, Deloitte

  • 5:55pm
    Closing Remarks

    Frederick Studemann, Literary Editor, Financial Times

  • 6:00pm
    Close of Event and Networking Reception

Speakers (5)

Tino Sorge, MP

Tino Sorge, MP

Member of the Committee on Health
German Bundestag
Thomas Müller

Thomas Müller

Head of Directorate General , Drugs, Medical Devices, Biotechnology
Federal Ministry of Health, Germany

Thomas Müller s a medical doctor and pharmacist. He completed his studies in Berlin and London, and then worked as medical doctor in the Dermatology Department of the University Hospital Charité in Berlin. He completed postgraduate studies in business administration. Subsequently, he worked for several years in the Hospital Pharmacy Departments of the University Hospitals of Erlangen and Rostock. He became director of the hospital pharmacy and the medical purchaser of the University Hospital of Rostock. From 2007 to 2018, Thomas Mueller was head of the Pharmaceuticals Department of the Federal Joint Committee (GBA) in Berlin. As part of his work at the GBA, Dr has played a key role in successfully designing, planning, and implementing the early benefit assessment and pricing of new pharmaceuticals in accordance with The Act on the Reform of the Market for Medical Products (Arzneimittelmarkt-Neuordnungsgesetz—AMNOG)., Since 2018, he has held the position of head of Directorate General, Drugs, Medical Devices, Biotechnology, at the Federal Ministry of Health in Germany. He is Assistant Professor at the University of Bonn (Regulatory Drug Affairs) and Paris-Sorbonne (International Market Access). 

Martin Bornhäuser

Martin Bornhäuser

Director, Department of Internal Medicine I and National Center for Tumor Diseases (NCT/UCC)
University Hospital Carl Gustav Carus TU Dresden

Professor Martin Bornhäuser he joined the directorate of the National Center for Tumor Diseases (www.nct.de) in Dresden in 2016. In his current position, he has a portfolio of responsibilities encompassing clinical service, head of the Good manufacturing laboratories, coordinating translational research and lecturer in Medical Studies and for the Master’s course in Regenerative Medicine. He is also an elected member of the Internal Medical Faculty at TU Dresden.

Throughout his clinical career, Professor Bornhäuser has focussed on translational research studies in the area of acute myeloid leukaemia and hematopoietic cell transplantation. Following his initial appointment at the University Hospital in Dresden as Professor of Haematology/Oncology in 2011, he later stepped up to the position of Co-Director of the  hospital’s Medical Clinic I. He was one of the founding members of the Center of Regenerative Therapy Dresden and developed additional expertise in the areas of stem cell biology and adoptive cellular therapy.. In addition to his responsibilities at the University of Dresden, in 2015, Professor Bornhäuser became a Visiting Professor at the Department of Haematology at King’s College London, UK. 

Rainer Göbel

Rainer Göbel

Associate
Deutsche Leukamie & Lymphom-Hilfe (DLH)

My life started in 1966. While studying Chemistry and Pharmacy, I worked on a number of IT projects and became an entrepreneur developing software using databases. The Chronic Myeloid Leukaemia (CML) diagnosis in 2000 had a major impact on my life, my job and my family.

I got involved with a leukaemia self-help group in Berlin and in 2012 I became member of the board of the German Leukaemia and Lymphoma Aid (DLH) – as well as other haematological patient organisations. One of our aims is to have good information materials available for patients. Therefore, as part of our role we write and distribute brochures and fact sheets. I take part in guideline working groups for several diseases and represent the patients' interests in the political context.

After nine and a half years, I was able to stop therapy. Since 2016, I have worked for the Joint Cancer Registry (GKR), initially as an IT specialist, and now as head of IT. Occasionally I work on scientific studies, for instance, related to cancer and poverty.

Dennis Frerichs

Dennis Frerichs

General Manager
Gilead Sciences GmbH

Mr. Dennis Frerichs is interim General Manager and member of the Management Board of Gilead Sciences Germany since 2018. He previously held the position of General Manager at Gilead Sciences Netherlands for two years. Frerichs had already supported Gilead Sciences Germany in 2014-2016, first as Business Director HIV and then as Business Director Hepatitis. Prior to joining Gilead Sciences, he worked at AstraZeneca in the USA and Germany, as Global Brand Manager and in various sales and marketing positions.

fallback

Chair and Moderator (2)

Frederick  Studemann

Frederick Studemann

Literary Editor
Financial Times

Frederick Studemann is the Comment and Analysis editor and member of the editorial board of the Financial Times. In his present role, he oversees the opinion and analysis coverage of the FT online and in the paper as well as the management features. He joined the FT in 1996 as Berlin Correspondent and has held a variety of posts including UK Correspondent, Political Correspondent and European News Editor. He was a member of the launch team of Financial Times Deutschland, the FT's German-language sister paper, where he established and ran the Features and Weekend sections. Born in the USA, he grew up in Ireland, the UK, the Soviet Union and Greece; he was educated in Britain and currently lives with his family in London.

Sebastian Krolop

Sebastian Krolop

Partner and Industry Lead, Life Sciences and Health Care
Deloitte

Sebastian Krolop is a Partner and Industry Lead, Life Sciences and Health Care with Deloitte. With almost 20 years of professional experience, he is a national and international respected expert, bringing together Strategy, Transformation and Transaction. Dr Krolop attended medical school in Germany and the USA, and practiced Anaesthesiology at the University Hospital of Heidelberg.  After receiving a Master of Science degree in Business Administration, he joined the Boston Consulting Group as a member of the Financial Service Practice. Later, with Accenture, he was a Partner, Strategy Healthcare (GSA) and then with Philips, he was a Vice President and Partner of the company’s Healthcare Transformation Service (EMEA). Dr Krolop is also a past Chair of the Worldwide Board of Directors of the Healthcare Information and Management System Society (HIMSS), has a lectureship at the Fresenius University and is author and co-author of numerous books, to include the annual Hospital Rating Reports and the Nursing Home and Rehabilitation Rating Reports. 

Who Attends

Join thought leaders from politics, medicine, the healthcare sector and the public sector at this intimate forum to discuss a variety of issues, from the potential benefits to patients and healthcare systems to the future of personalised medicine.

Registration is limited. To apply for a complimentary place, please request an invitation.

Please note that all applications are subject to review and approval.

fallback

Venue

Hilton Berlin
Mohrenstraße 30
Berlin 10117

Germany


fallback

PRESENTED BY (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.

In Association with (1)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Contact Us

Che Wheatley
Marketing, Media Partnership and Delegate enquiries
Financial Times
Francesca Perkins
Event Manager
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Eden Kyle
Press Enquiries
Financial Times